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BACKGROUND
Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk 
of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug 
that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascu-
lar events further is not known.
METHODS
We conducted a double-blind, randomized trial involving 18,144 patients who had 
been hospitalized for an acute coronary syndrome within the preceding 10 days and 
had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) 
if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 
3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination 
of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin–ezetimibe) was com-
pared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The pri-
mary end point was a composite of cardiovascular death, nonfatal myocardial 
infarction, unstable angina requiring rehospitalization, coronary revascularization 
(≥30 days after randomization), or nonfatal stroke. The median follow-up was 6 years.
RESULTS
The median time-weighted average LDL cholesterol level during the study was 53.7 mg 
per deciliter (1.4 mmol per liter) in the simvastatin–ezetimibe group, as compared 
with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy 
group (P<0.001). The Kaplan–Meier event rate for the primary end point at 7 years 
was 32.7% in the simvastatin–ezetimibe group, as compared with 34.7% in the 
simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; 
hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-
specified muscle, gallbladder, and hepatic adverse effects and cancer were similar 
in the two groups.
CONCLUSIONS
When added to statin therapy, ezetimibe resulted in incremental lowering of LDL 
cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL 
cholesterol to levels below previous targets provided additional benefit. (Funded 
by Merck; IMPROVE-IT ClinicalTrials.gov number, NCT00202878.)
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The use of 3-hydroxy-3-methylgluta-ryl-coenzyme A reductase inhibitors (statins) reduces both low-density lipoprotein (LDL) 
cholesterol levels and the risk of cardiovascular 
events in patients with and those without car-
diovascular disease.1-4 Intensive statin therapy, as 
compared with moderate-dose statin therapy, 
incrementally lowers LDL cholesterol levels and 
rates of nonfatal cardiovascular events.5-9 Because 
of the residual risk of recurrent cardiovascular 
events and safety concerns associated with high-
dose statin therapy,10 additional lipid-modifying 
therapies have been sought.11-14
Ezetimibe targets the Niemann–Pick C1–like 1 
(NPC1L1) protein, thereby reducing absorption 
of cholesterol from the intestine.15,16 When added 
to statins, ezetimibe reduces LDL cholesterol 
levels by an additional 23 to 24%, on average.17,18 
Polymorphisms affecting NPC1L1 are associated 
with both lower levels of LDL cholesterol and a 
lower risk of cardiovascular events.19 Whether 
further lowering of LDL cholesterol levels achieved 
with the addition of ezetimibe to statin therapy 
leads to a benefit in clinical outcomes is un-
known. The Improved Reduction of Outcomes: 
Vytorin Efficacy International Trial (IMPROVE-IT) 
evaluated the effect of ezetimibe combined with 
simvastatin, as compared with that of simva-
statin alone, in stable patients who had had an 
acute coronary syndrome and whose LDL choles-
terol values were within guideline recommenda-
tions.20-24
Me thods
Study Oversight
The trial was designed and led by an executive 
committee that included representatives from the 
Thrombolysis in Myocardial Infarction (TIMI) 
Study Group, the Duke Clinical Research Insti-
tute (DCRI), and the study sponsor (Merck), in 
collaboration with an international steering com-
mittee (see the Supplementary Appendix, available 
with the full text of this article at NEJM.org).22-24 
The ethics committee at each participating center 
approved the protocol and amendments. A data 
and safety monitoring board oversaw the study. 
DCRI managed the database and performed the 
primary analyses independently using raw data; 
TIMI and the sponsor verified the analyses. All 
the authors vouch for the completeness and ac-
curacy of the data and all analyses, as well as for 
the fidelity of this report to the trial protocol, 
which is available at NEJM.org.
Patient Population
Men and women who were at least 50 years of 
age were eligible for inclusion if they had been 
hospitalized within the preceding 10 days for an 
acute coronary syndrome (an acute myocardial 
infarction, with or without ST-segment elevation 
on electrocardiography, or high-risk unstable 
angina22-24; detailed definitions are provided in 
the Supplementary Appendix). Patients were re-
quired to have an LDL cholesterol level of 50 mg 
per deciliter (1.3 mmol per liter) or higher. For 
participants who were not receiving long-term 
lipid-lowering therapy, the maximum LDL choles-
terol level for enrollment was 125 mg per deciliter 
(3.2 mmol per liter); for participants who were 
receiving lipid-lowering therapy, the maximum 
level was 100 mg per deciliter (2.6 mmol per liter). 
The LDL cholesterol level for eligibility was mea-
sured locally within the first 24 hours after onset 
of the acute coronary syndrome. Key exclusion 
criteria were planned coronary-artery bypass 
grafting for the acute coronary syndrome event, 
creatinine clearance of less than 30 ml per min-
ute, active liver disease, or use of statin therapy 
that had LDL cholesterol–lowering potency great-
er than 40 mg of simvastatin (see the Supple-
mentary Appendix). Each patient provided writ-
ten informed consent.
Study Protocol
Patients received standard medical and interven-
tional treatment for acute coronary syndrome22 
and were randomly assigned, in a 1:1 ratio and 
in a double-blind fashion, to receive, once daily, 
either simvastatin (at a dose of 40 mg) plus 
ezetimibe (at a dose of 10 mg) (simvastatin–
ezetimibe group) or simvastatin (at a dose of 
40 mg) plus placebo (simvastatin-monotherapy 
group). Randomization was stratified according 
to prior use of lipid-lowering therapy, type of 
acute coronary syndrome, and status with respect 
to enrollment in the concurrent Early Glycopro-
tein IIb/IIIa Inhibition in Non–ST-Segment Ele-
vation Acute Coronary Syndrome (EARLY ACS) 
trial.25
Patients had follow-up visits at 30 days, at 
4 months, and every 4 months thereafter. Patients 
who discontinued the study drug during the trial 
were generally followed by means of telephone 
A Quick Take 
summary is 
available at 
NEJM.org
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV STUDI LA SAPIENZA on September 23, 2018. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 372;25 nejm.org June 18, 2015 2389
Ezetimibe and Statin after Acute Coronary Syndromes
calls. Blood samples were obtained at random-
ization, at 1, 4, 8, and 12 months, and yearly 
thereafter for those attending clinic visits.
For patients in either study group who had 
LDL cholesterol levels higher than 79 mg per 
deciliter (2.0 mmol per liter) on two consecutive 
measurements, the simvastatin dose was in-
creased to 80 mg in a double-blind manner. In 
June 2011, in accordance with Food and Drug 
Administration guidance for limiting new pre-
scriptions of 80 mg of simvastatin, patients were 
no longer eligible for an increased dose of sim-
vastatin to 80 mg, and any patient who had been 
receiving the 80-mg dose for less than 1 year 
had the dose reduced to 40 mg.23 If an LDL cho-
lesterol measurement on the new regimen was 
confirmed to be higher than 100 mg per decili-
ter, the study drug could be discontinued and 
more potent therapy initiated. The study contin-
ued until each patient had been followed for a 
minimum of 2.5 years and until the target num-
ber of events (5250) was reached. Five amend-
ments to the protocol were implemented during 
the course of the study, including an increase in 
the sample size.23
End Points
The primary efficacy end point was a composite 
of death from cardiovascular disease, a major 
coronary event (nonfatal myocardial infarction, 
documented unstable angina requiring hospital 
admission, or coronary revascularization occur-
ring at least 30 days after randomization), or 
nonfatal stroke, assessed from the time of ran-
domization until the first occurrence of one of 
the events. The three secondary efficacy end 
points were a composite of death from any cause, 
major coronary event, or nonfatal stroke; a com-
posite of death from coronary heart disease, non-
fatal myocardial infarction, or urgent coronary 
revascularization 30 days or more after random-
ization; and a composite of death from cardio-
vascular causes, nonfatal myocardial infarction, 
hospitalization for unstable angina, all revascu-
larization 30 days or more after randomization, 
or nonfatal stroke. All end-point definitions are 
described in the Supplementary Appendix.22-24 
Prespecified safety variables included liver en-
zyme levels and creatine kinase levels, episodes 
of myopathy or rhabdomyolysis, gallbladder-
related adverse events, and cancer. Independent 
clinical-events committees, whose members were 
unaware of the study-group assignments, adjudi-
cated primary end-point events (excluding revas-
cularization), cancer, and muscle-related events 
(details are provided in the Supplementary Ap-
pendix).
Statistical Analysis
In the final protocol, we estimated that 5250 
events would be required to give the study 90% 
power to detect a 9.375% lower relative risk for 
the primary end point with simvastatin–ezetimibe 
than with simvastatin monotherapy. All efficacy 
and safety analyses were performed in the inten-
tion-to-treat population. Rules for stopping the 
study early at interim analyses were prespeci-
fied.22-24 The data and safety monitoring board 
conducted 10 safety reviews. In addition, three 
interim efficacy analyses were performed, after 
45.7%, 76.1%, and 86.9% of the required events 
had occurred; adjustment of the level of signifi-
cance to account for the three interim analyses 
was determined by the Lan–DeMets approxima-
tion of the O’Brien–Fleming boundaries for group 
sequential testing, with a final two-sided P value 
for significance of 0.0394 or less. The false 
positive error rate for the three secondary end 
points was controlled with the use of the Hoch-
berg method.26 A nominal P value of 0.05 or less 
without adjustment for multiple testing was used 
for other end points. Estimates of the hazard 
ratios and associated 95% confidence intervals 
for the comparison of simvastatin–ezetimibe with 
simvastatin monotherapy were obtained with the 
use of a Cox proportional-hazards model, with 
study group and stratification factors as covari-
ates. Event rates are Kaplan–Meier failure rates 
at 7 years. Data for the analyses in this report 
were based on the database that was locked on 
October 21, 2014. Additional updating of data 
on serious adverse events and hospitalizations 
was carried out after this database lock (see the 
Supplementary Appendix).
R esult s
Patients
Between October 26, 2005, and July 8, 2010, a 
total of 18,144 patients underwent randomization 
at 1147 sites in 39 countries. The disposition of 
the patients is shown in Figure S1 in the Supple-
mentary Appendix; 9077 were assigned to the 
simvastatin-monotherapy group, and 9067 to the 
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Variable
Simvastatin Monotherapy 
(N = 9077)
Simvastatin–Ezetimibe 
(N = 9067)
Demographic characteristic
Age — yr 63.6±9.8 63.6±9.7
Male — no. (%) 6886 (75.9) 6842 (75.5)
White race — no. (%)† 7624 (84.0) 7578 (83.6)
Weight — kg 83.0±17.4 82.9±17.4
Body-mass index‡ 28.3±5.2 28.3±5.2
Region — no. (%)
North America 3487 (38.4) 3486 (38.4)
Western Europe 3641 (40.1) 3633 (40.1)
Eastern Europe 707 (7.8) 709 (7.8)
Asia Pacific 448 (4.9) 448 (4.9)
South America 794 (8.7) 791 (8.7)
Coexisting conditions — no./total no. (%)
Diabetes 2474/9077 (27.3) 2459/9067 (27.1)
Hypertension 5557/9072 (61.3) 5580/9063 (61.6)
Congestive heart failure 371/9077 (4.1) 419/9067 (4.6)
Peripheral arterial disease 518/9077 (5.7) 487/9067 (5.4)
Current smoker — no./total no. (%) 3035/9072 (33.5) 2943/9067 (32.5)
Previous MI — no./total no. (%) 1881/9077 (20.7) 1925/9054 (21.3)
Previous PCI — no. (%) 1796 (19.8) 1766 (19.5)
Previous CABG — no. (%) 842 (9.3) 842 (9.3)
Before index ACS
Medications — no./total no. (%)
Lipid-lowering agent 3207/9063 (35.4) 3227/9067 (35.6)
Statin 3111/9077 (34.3) 3135/9067 (34.6)
Aspirin 3855/9077 (42.5) 3799/9067 (41.9)
Creatinine clearance — ml/min
Median 84.7 84.4
Interquartile range 65.8–107.4 65.8–106.5
At index event
Type of event — no./total no. (%)
MI with ST-segment elevation 2606/9077 (28.7) 2584/9067 (28.5)
MI without ST-segment elevation 4253/9077 (46.9) 4302/9061 (47.5)
Unstable angina 2211/9077 (24.4) 2175/9067 (24.0)
Diagnostic catheterization — no./total no. (%) 7936/9069 (87.5) 7988/9059 (88.2)
Prerandomization PCI — no./total no. (%) 6321/9071 (69.7) 6385/9061 (70.5)
Mean LDL cholesterol — mg/dl§ 93.8 93.8
Time from ACS to randomization — days
Median 5.0 5.0
Interquartile range 3.0–8.0 3.0–8.0
Medications at time of randomization — no./total no. (%)
Aspirin 8794/9077 (96.9) 8798/9063 (97.1)
Table 1. Baseline Characteristics.*
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simvastatin–ezetimibe group. The baseline char-
acteristics of the patients in the two study 
groups were well matched (Table 1). The average 
age of the patients was 64 years, 24% were 
women, 27% had diabetes mellitus, 88% had 
undergone coronary angiography and 70% had 
undergone percutaneous coronary intervention 
during the index hospitalization, 34% were tak-
ing statin drugs at the time of the index event, 
and 77% received statin therapy during hospital-
ization.
The simvastatin dose was increased to 80 mg 
for elevated LDL cholesterol levels in 27% of the 
patients in the simvastatin-monotherapy group 
and in 6% of the patients in the simvastatin–
ezetimibe group. The numbers of patients who 
discontinued the study drug, withdrew consent, 
or were lost to follow-up were similar in the two 
groups (Fig. S1 in the Supplementary Appendix). 
After a median of 6 years, 42% of the patients in 
each group had discontinued the study medica-
tion without having died or without having had 
a primary end-point event. The percentage of 
potential follow-up that was achieved — calcu-
lated as (number of patient-years of follow-up ÷ 
potential patient-years of follow-up) × 100 — 
was 91% for the primary end point and 97% for 
all-cause mortality.
Lipid Data
At the time of hospitalization for the index event, 
the mean LDL cholesterol level was 93.8 mg per 
deciliter (2.4 mmol per liter) in each group 
(Table 1). Among patients who had blood sam-
ples obtained at 1 year, the mean LDL choles-
terol level was 69.9 mg per deciliter (1.8 mmol 
per liter) in the simvastatin-monotherapy group 
and 53.2 mg per deciliter (1.4 mmol per liter) 
in the simvastatin–ezetimibe group (P<0.001) 
(Table S1 in the Supplementary Appendix). This 
difference of 16.7 mg per deciliter (0.43 mmol 
per liter) (P<0.001) represented a 24% further 
lowering of LDL cholesterol level when ezetimibe 
was combined with simvastatin than when sim-
vastatin was administered alone. Over the course 
of the entire trial, the median time-weighted 
average LDL cholesterol level was 69.5 mg per 
deciliter (1.8 mmol per liter) in the simvastatin-
monotherapy group and 53.7 mg per deciliter 
(1.4 mmol per liter) in the simvastatin–ezeti-
mibe group. To account for patients in the two 
groups who discontinued treatment and did not 
have blood samples obtained, LDL cholesterol 
levels were imputed with the use of the LDL 
cholesterol levels measured at randomization 
(the approach used by the Cholesterol Treatment 
Trialists [CTT] collaborators).3,4 The between-
group difference in LDL cholesterol level at 1 year 
with imputation was 12.8 mg per deciliter 
(0.33 mmol per liter).
At 1 year, levels of total cholesterol, triglyc-
erides, non–high-density lipoprotein (HDL) cho-
lesterol, apolipoprotein B, and high-sensitivity 
C-reactive protein were all significantly lower 
in the simvastatin–ezetimibe group than in the 
simvastatin-monotherapy group (Table S1 in the 
Supplementary Appendix). A greater proportion 
of patients in the simvastatin–ezetimibe group 
than in the simvastatin-monotherapy group 
achieved the dual goal of an LDL cholesterol 
level of less than 70 mg per deciliter (1.8 mmol 
per liter) and a high-sensitivity C-reactive protein 
Variable
Simvastatin Monotherapy 
(N = 9077)
Simvastatin–Ezetimibe 
(N = 9067)
Thienopyridine 7813/9077 (86.1) 7869/9067 (86.8)
Beta-blocker 7879/9077 (86.8) 7912/9067 (87.3)
ACE inhibitor or ARB 6878/9077 (75.8) 6822/9063 (75.3)
*  Plus–minus values are means ±SD. No significant differences were noted between the groups. ACE denotes angiotensin-
converting enzyme, ACS acute coronary syndrome, ARB angiotensin-receptor blocker, CABG coronary-artery bypass 
grafting, LDL low-density lipoprotein, MI myocardial infarction, and PCI percutaneous coronary intervention.
†  Race was determined by the investigators.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Data on baseline levels were available for 9009 participants in the simvastatin-monotherapy group and for 8990 partici-
pants in the simvastatin–ezetimibe group; data on 1-year levels were available for 6939 participants in the simvastatin-
monotherapy group and for 6864 participants in the simvastatin–ezetimibe group. To convert the values for cholesterol 
to millimoles per liter, multiply by 0.02586.
Table 1. (Continued.)
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level of less than 2.0 at 1 month (50.6% vs. 30.5%) 
(Table S2 in the Supplementary Appendix).
Efficacy End Points
Kaplan–Meier event rates for the primary end 
point at 7 years were 32.7% in the simvastatin–
ezetimibe group and 34.7% in the simvastatin-
monotherapy group (absolute risk reduction, 
2.0 percentage points; hazard ratio, 0.936; 95% 
confidence interval, 0.89 to 0.99; P = 0.016) 
(Fig. 1). The benefit appeared to emerge after 
1 year. The rate of each of the three secondary 
end points was significantly lower in the simva-
statin–ezetimibe group than in the simvastatin-
monotherapy group (Table 2).
The rates of death from cardiovascular causes 
and from any cause were similar in the two 
groups. The risk of any myocardial infarction 
was significantly lower with simvastatin–ezeti-
mibe than with simvastatin monotherapy (differ-
ence, 1.7 percentage points; hazard ratio, 0.87; 
P = 0.002), as was the risk of ischemic stroke 
(difference, 0.7 percentage points; hazard ratio, 
0.79; P = 0.008) (Table 2). There was a nonsignifi-
cantly higher risk of hemorrhagic stroke with 
simvastatin–ezetimibe than with simvastatin 
monotherapy (difference, 0.2 percentage points; 
hazard ratio, 1.38; P = 0.11), although the num-
ber of hemorrhagic strokes was low.
The rate of the composite end point of death 
from cardiovascular causes, myocardial infarc-
tion, or stroke was significantly lower, by 1.8 
percentage points, in the simvastatin–ezetimibe 
group than in the simvastatin-monotherapy group 
(hazard ratio, 0.90; P = 0.003) (Table 2). The rate 
of major vascular events as defined by the CTT 
collaborators3,4 (a composite of death from coro-
nary heart disease, myocardial infarction, stroke, 
or coronary revascularization 30 days or more 
after randomization) was also significantly lower 
in the simvastatin–ezetimibe group (difference, 2.2 
percentage points; hazard ratio, 0.928; P = 0.007).
The benefit of simvastatin–ezetimibe was con-
sistent across nearly all prespecified subgroups 
(Fig. S2 in Supplementary Appendix). The bene-
fit appeared to be particularly pronounced in 
patients with diabetes mellitus and in patients 
75 years of age or older.
Safety
No significant between-group differences were 
seen in the percentage of patients who had ele-
vations in alanine aminotransferase levels that 
exceeded three times the upper limit of the nor-
mal range or in the rates of gallbladder-related 
adverse events, cholecystectomy, muscle-related 
adverse events, or new, relapsing, or worsening 
cancer (Table 3). Discontinuation of study medi-
cation owing to an adverse event occurred in 
10.1% of the patients in the simvastatin-mono-
therapy group and in 10.6% of those in the 
simvastatin–ezetimibe group.
Discussion
In IMPROVE-IT, the addition to statin therapy of 
a nonstatin agent, ezetimibe, which reduces the 
absorption of cholesterol from the gastrointesti-
nal tract, lowered LDL cholesterol by approxi-
mately 24%. The combination of simvastatin and 
ezetimibe also resulted in a significantly lower 
risk of cardiovascular events than that with 
statin monotherapy, with a 2.0-percentage-point 
lower rate of the primary composite end point of 
Figure 1. Kaplan–Meier Curves for the Primary Efficacy End Point.
Shown are the cumulative event rates for the primary composite end point 
of death from cardiovascular disease, a major coronary event (nonfatal 
myocardial infarction, documented unstable angina requiring hospital ad-
mission, or coronary revascularization occurring at least 30 days after ran-
domization), or nonfatal stroke in the intention-to-treat population during 
the overall study period (i.e., beginning from the time of randomization to 
the day of the first occurrence of a primary end-point event, the day of the 
last office or phone visit, or the day of death during follow-up). The inset 
shows the same data on an enlarged y axis.
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Outcome
Simvastatin 
Monotherapy 
(N = 9077)
Simvastatin–
Ezetimibe 
(N = 9067)
Hazard Ratio 
(95% CI) P Value
no. of patients (%)
Primary end point: death from cardiovascular causes, major coronary 
event, or nonfatal stroke
2742 (34.7) 2572 (32.7) 0.936 
(0.89–0.99)
0.016
Secondary end points
Death from any cause, major coronary event, or nonfatal stroke 3246 (40.3) 3089 (38.7) 0.95 
(0.90–1.0)
0.03
Death from coronary heart disease, nonfatal MI, urgent coronary 
revascularization ≥30 days
1448 (18.9) 1322 (17.5) 0.91 
(0.85–0.98)
0.02
Death from cardiovascular causes, nonfatal MI, hospitalization 
for unstable angina, all revascularization ≥30 days, nonfatal 
stroke
2869 (36.2) 2716 (34.5) 0.95 
(0.90–1.0)
0.04
Tertiary end points†
Death from any cause 1231 (15.3) 1215 (15.4) 0.99 
(0.91–1.07)
0.78
Death from cardiovascular causes 538 (6.8) 537 (6.9) 1.00 
(0.89–1.13)
1.00
Death from coronary heart disease 461 (5.8) 440 (5.7) 0.96 
(0.84–1.09)
0.50
Any MI 1118 (14.8) 977 (13.1) 0.87  
(0.80–0.95)
0.002
Nonfatal MI 1083 (14.4) 945 (12.8) 0.87 
(0.80–0.95)
0.002
Fatal MI 49 (0.7) 41 (0.5) 0.84  
(0.55–1.27)
0.41
Any stroke 345 (4.8) 296 (4.2) 0.86 
(0.73–1.00)
0.05
Ischemic stroke 297 (4.1) 236 (3.4) 0.79 
(0.67–0.94)
0.008
Hemorrhagic stroke 43 (0.6) 59 (0.8) 1.38 
(0.93–2.04)
0.11
Coronary revascularization ≥30 days after randomization 1793 (23.4) 1690 (21.8) 0.95 
(0.89–1.01)
0.11
Urgent coronary revascularization ≥30 days after randomization 626 (8.6) 510 (7.0) 0.81 
(0.72–0.91)
0.001
Any revascularization ≥30 days after randomization 1962 (25.6) 1871 (24.2) 0.96 
(0.90–1.02)
0.18
Hospitalization for unstable angina 148 (1.9) 156 (2.1) 1.06 
(0.85–1.33)
0.62
Other prespecified end points
Death from cardiovascular causes, MI, or stroke 1704 (22.2) 1544 (20.4) 0.90  
(0.84–0.96)
0.003
Major vascular events: death from coronary heart disease, MI, 
stroke, or coronary revascularization ≥30 days after random-
ization‡
2685 (34.0) 2498 (31.9) 0.928 
(0.88–0.98)
0.007
*  The database for the analysis presented here was locked on October 21, 2014. Percentages are 7-year Kaplan–Meier estimates. Major coro-
nary events included MI, hospitalization for unstable angina, and coronary revascularization 30 or more days after randomization.
†  The individual end points listed are the first occurrence of that event.
‡  The end point of major vascular events was defined according to the definition used by the Cholesterol Treatment Trialists’ collaborators.
Table 2. Primary, Secondary, and Individual End Points.*
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cardiovascular death, major coronary events, or 
nonfatal stroke (hazard ratio, 0.936). No be-
tween-group differences in cardiovascular mor-
tality or in the rate of death from any cause were 
anticipated or observed in IMPROVE-IT, findings 
that are consistent with those in trials of inten-
sive-dose versus standard-dose statin therapy.5-9 
However, significant reductions were observed 
in the rates of myocardial infarction and isch-
emic stroke.
The extent of benefit afforded by the simvas-
tatin–ezetimibe combination is consistent with 
that seen in previous statin trials, with a similar 
reduction in cardiovascular events according to 
the degree of LDL cholesterol lowering 
(Fig. 2).1,2,27-38 Using the approach and end point 
that were used by the CTT collaborators,3,4 we 
observed a between-group difference in LDL 
cholesterol levels (with imputation for missing 
values) of 12.8 mg per deciliter and a propor-
tional 7.2% lower rate of major vascular events, 
a finding consistent with the reduction produced 
by statins. The hazard ratio for clinical benefit 
per millimole of LDL cholesterol reduction with 
ezetimibe in IMPROVE-IT was 0.80, as com-
pared with 0.78 observed with statins in the CTT 
meta-analysis.3,4 This trial cannot prove that the 
effect was mediated by the lowering of LDL cho-
lesterol levels alone, since changes in other lipo-
proteins and high sensitivity C-reactive protein 
may have played a role. However, the consistency 
with expectations from the CTT analysis, in 
which a different class of drug was used, pro-
vides further evidence for a relationship between 
lipid lowering and improved outcomes. The ob-
servation that a nonstatin lipid-lowering agent 
can also reduce cardiovascular risk does indi-
rectly support the LDL hypothesis (i.e., that 
lowering LDL cholesterol leads to a reduction in 
cardiovascular events), but most importantly it 
undercuts the “statin hypothesis,” that somehow 
only statins are beneficial. This finding is no-
table in that several previous trials have failed to 
show a significant benefit of nonstatin lipid-
modifying agents when added to statins.11-14
According to practice guidelines in place at 
the time of patient enrollment in IMPROVE-IT, 
treatment of hypercholesterolemia was based on 
lowering LDL cholesterol to target levels,20,21 
which were set on the basis of a patient’s risk of 
cardiovascular events. Over the past two de-
cades, statin trials have shown clinical benefit 
when LDL cholesterol was lowered to progres-
sively lower levels.1-9 On the basis of these trials, 
a target LDL cholesterol of less than 70 mg per 
deciliter has been recommended for patients 
End Point
Simvastatin Monotherapy 
(N = 9077)
Simvastatin–Ezetimibe 
(N = 9067) P Value
no. of patients (%)
ALT, AST, or both ≥3× ULN 208 (2.3) 224 (2.5) 0.43
Cholecystectomy 134 (1.5) 133 (1.5) 0.96
Gallbladder-related adverse events 321 (3.5) 281 (3.1) 0.10
Rhabdomyolysis 18 (0.2) 13 (0.1) 0.37
Myopathy 10 (0.1) 15 (0.2) 0.32
Rhabdomyolysis or myopathy 28 (0.3) 27 (0.3) 0.90
Rhabdomyolysis, myopathy, myalgia with cre-
atine kinase elevation ≥5× ULN
58 (0.6) 53 (0.6) 0.64
Cancer† 732 (10.2) 748 (10.2) 0.57
Death from cancer† 272 (3.6) 280 (3.8) 0.71
*  Adverse events were assessed in the intention-to-treat population. The database for the analysis presented here was 
locked on October 21, 2014. All muscle and cancer events were adjudicated by a clinical events committee, whose 
members were unaware of the study-group assignments. Detailed definitions of the adverse events are provided in the 
Supplementary Appendix. ALT denotes alanine aminotransferase, AST aspartate aminotransferase, and ULN upper lim-
it of the normal range.
†  Percentages for cancer are 7-year Kaplan–Meier estimates. Cancer includes any new, relapsing, or progressing cancer, 
excluding nonmelanoma skin cancer. Death from cancer includes death from nonmelanoma skin cancer.
Table 3. Prespecified Safety End Points.*
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after an acute coronary syndrome.20,21 Whether 
additional clinical benefit would be observed 
with further reductions of LDL cholesterol to 
levels below 70 mg per deciliter has not been 
clear. The benefit of ezetimibe in IMPROVE-IT 
suggests that there is additional clinical benefit, 
and it appeared to be similar in patients with 
lower LDL cholesterol levels as well as in those 
with higher LDL cholesterol levels at baseline.
There were no significant differences be-
tween the two study groups in any of the pre-
specified safety end points or in the rate of 
discontinuation of study medication owing to 
adverse events, albeit with a higher use of the 
80-mg simvastatin dose in the simvastatin-
monotherapy group than in the simvastatin–
ezetimibe group. The rate of hemorrhagic stroke 
was higher, although not significantly so, with 
simvastatin–ezetimibe than with simvastatin 
monotherapy, a finding similar to that seen with 
statin therapy as compared with placebo.3,4 Al-
though cautions had been raised about the safety 
of ezetimibe,39,40 we observed no significant 
between-group difference in the incidence of 
cancer or cancer deaths during up to 7 years of 
follow-up and no significant difference in the 
incidence of rhabdomyolysis or myopathy.
Several limitations of our study should be 
considered. First, we evaluated patients who had 
had an acute coronary syndrome, and our results 
are most relevant to that population. However, 
the treatment period extended for an average of 
6 years, and the differences between the two 
treatment groups emerged after about 1 year, by 
which time most of the data were from patients 
in the chronic phase of their disease. Second, we 
used 40 mg and 80 mg of simvastatin as back-
ground statin therapy (categorized as “moderate” 
and “intensive” statin therapy, respectively) with 
an upper limit for LDL cholesterol level at study 
entry to ensure that this statin regimen would 
be likely to reduce LDL cholesterol levels to less 
than 70 mg per deciliter (on average), as recom-
mended at the time of patient enrollment in the 
trial.20,21 Although we studied only this regimen, 
current data indicate that the same relationship 
between reduction in LDL cholesterol levels and 
clinical benefit is seen across different statins 
and statin doses.4 It is possible, as others have 
suggested,41 that greater benefits from ezetimibe 
might have been seen if baseline LDL cholesterol 
levels had been higher. Finally, 42% of the pa-
tients discontinued the study medication for any 
reason prematurely, with an equal proportion in 
the two groups. This rate of approximately 7% 
per year is similar to or better than that achieved 
Figure 2. Plot of the IMPROVE-IT Trial Data and Statin Trials for Change  
in Low-Density Lipoprotein (LDL) Cholesterol versus Clinical Benefit.
The hazard ratio (obtained with the use of a Cox proportional-hazards model) 
for the reduction in major vascular events in the simvastatin–ezetimibe 
group as compared with the simvastatin-monotherapy group in IMPROVE-IT 
is plotted against data from other trials of statins that assessed the associa-
tion between change in LDL and clinical benefit. Major vascular events were 
defined as a composite of death from coronary heart disease, myocardial 
infarction, stroke, or revascularization more than 30 days after randomiza-
tion. Vertical bars indicate 1 SE. The size of the box is proportional to the 
number of end points in the study. In IMPROVE-IT, the between-group dif-
ference in LDL cholesterol was calculated as the difference in the observed 
LDL cholesterol level in patients from whom blood samples were obtained 
at 1 year, with imputation of the value measured at the time of randomiza-
tion for patients from whom a blood sample was not obtained or was miss-
ing (including those who had died). Letters from a to n denote the follow-
ing trials: a: Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto 
Miocardico (GISSI Prevenzione)27; b: Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial–Lipid Lowering Trial (ALLHAT-LLT)28; 
c: Assessment of Lescol in Renal Transplantation (ALERT)29; d: Lescol Inter-
vention Prevention Study (LIPS)30; e: Air Force/Texas Coronary Atheroscle-
rosis Prevention Study (AFCAPS/TexCAPS)31; f: Cholesterol and Recurrent 
Events (CARE)32; g: Long-term Intervention with Pravastatin in Ischaemic 
Disease (LIPID)33; h: Prospective Study of Pravastatin in the Elderly at Risk 
(PROSPER)34; i: Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lower-
ing Arm (ASCOT-LLA)35; j: West of Scotland Coronary Prevention Study 
(WOSCOPS)36; k: Post–Coronary Artery Bypass Graft (Post CABG)37; l: 
 Collaborative Atorvastatin Diabetes Study (CARDS)38; m: Heart Protection 
Study (HPS)2; and n: Scandinavian Simvastatin Survival Study (4S)1.
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in some prior studies,5-7 but this trial had a par-
ticularly long duration of follow-up. We none-
theless found a significant benefit; if adherence 
had been higher, one might anticipate that a 
greater clinical benefit might have been seen.
In conclusion, the addition of ezetimibe to 
statin therapy in stable patients who had had an 
acute coronary syndrome and who had LDL cho-
lesterol levels within guideline recommendations 
further lowered the risk of cardiovascular events. 
The event reduction was consistent with the pre-
dicted effects seen with statins, even in the 
range of low LDL cholesterol levels in this trial, 
and no offsetting adverse events or toxic effects 
were observed.
Supported by Merck.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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